Skip to the content
  • Suomeksi
  • About Us
    • > Our role
    • > BoD and management
    • > Sustainability
  • Pharma Sector
    • > Feasibilities and inquiries
    • > Research archive
    • > References for post-licensure studies
  • Newsfeed
  • Contacts
  • Suomeksi

Tag: RSV

  • In category NewsPosted on 31.03.2023

    Why partner with FVR – Finnish Vaccine Research in studying vaccines for RSV?

    FVR’s unique network of ten clinical vaccine research clinics ensures good capacity and flexibility is available for conducting a successful study. ​Our expertise covers comprehensive clinical vaccine trials through phases 1-4, including register-based Real-World Evidence studies and large-scale pragmatic field trials, conducted together with healthcare providers​. Finland offers an excellent setting for a successful study […]

  • In category NewsPosted on 19.01.2023

    Moderna announces mRNA-1345, an investigational Respiratory Syncytial Virus (RSV) vaccine, has met primary efficacy endpoints in phase 3 trial in older adults

    On January 17th, Moderna announced positive topline data from its Phase 3 trial of mRNA-1345, an investigational mRNA vaccine targeting respiratory syncytial virus (RSV) in older adults. RSV, a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia, causes a particularly large burden of disease in infants and […]

  • In category NewsPosted on 11.11.2022

    Pfizer announces positive findings in global maternal immunization trial for its RSV vaccine candidate

    On November 1st, Pfizer announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal Immunization Study for Safety and Efficacy) investigating its RSV vaccine candidate, RSVpreF, when administered to pregnant participants to help protect their infants from RSV disease after birth. RSV is a contagious virus and a common cause of respiratory […]

  • In category NewsPosted on 16.09.2022

    New medicine to protect babies and infants from respiratory syncytial virus (RSV) infection

    European Medicines Agency (EMA) has recommended a marketing authorisation in the European Union for Beyfortus (nirsevimab) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in newborn babies and infants during their first RSV season. RSV can be serious, especially in infants. It is the most common cause of lower respiratory tract infections, […]

  • About Us
    • Our role
    • BoD and management
    • Sustainability
  • Pharma Sector
    • Feasibilities and inquiries
    • Research archive
    • References for post-licensure studies
  • Newsfeed
  • Contacts

FVR - Finnish Vaccine Research
Peltokatu 26, 33100 Tampere, Finland
info@fvr.fi Business ID FI32566594

  • About cookies

© Copyrights 2022 FVR – Finnish Vaccine Research